Whether acalatinib has been officially included in the medical insurance catalog and its explanation

Acalabrutinib is a selective Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat hematological cancer diseases such as mantle cell lymphoma and chronic lymphocytic leukemia. The drug has been approved for marketing in China in recent years and has become one of the important targeted drugs for patients to treat BTK-related diseases. Its precise mechanism of action and good efficacy have earned acotinib widespread attention in the field of hematological tumors.

At present, acotinib has been officially included in China's national medical insurance directory, which has greatly reduced the economic burden of medication on patients. Medical insurance coverage allows more patients to afford such high-priced targeted drugs and enjoy advanced treatment options. Patients can purchase acotinib at regular hospital pharmacies in China, and can enjoy a certain percentage of reimbursement according to the medical insurance policy. The specific reimbursement ratio and actual costs vary by region. Patients need to consult the local hospital or medical insurance department for detailed information.

In terms of price, the domestic original drug of acotinib is priced relatively high, usually reaching more than 20,000 yuan per box, which still puts some financial pressure on some patients. For this reason, some patients choose to purchase more affordable versions of generic drugs through overseas channels. In particular, the price of the generic acotinib drug produced in Laos is about more than 3,000 yuan, which is far lower than the price of the domestic original drug. The ingredients of the drug are basically the same as the original drug, and the efficacy is relatively reliable.

In general, the inclusion of acotinib in domestic medical insurance marks a significant increase in the accessibility of targeted drugs for the treatment of BTK-related diseases. Although the price is higher, medical insurance reimbursement helps ease the burden on patients. For patients with limited economic conditions, overseas generic drugs have become a feasible supplementary option, but when purchasing, they should ensure that the channels are formal and safe to ensure the quality and efficacy of the drugs. Patients should actively communicate with their doctors during the medication process and reasonably choose a treatment plan that suits them.

Reference materials:https://www.drugs.com